Arrowhead (ARWR) announced that it has earned a $100M milestone payment from Sarepta Therapeutics (SRPT). The milestone was triggered when Arrowhead reached the first of two prespecified enrollment targets and subsequent authorization to dose escalate in a Phase 1/2 clinical study of ARO-DM1, an investigational RNA interference therapeutic for the treatment of type 1 myotonic dystrophy, the most common adult-onset muscular dystrophy. Arrowhead currently expects to achieve the second enrollment target by the end of 2025, which would trigger an additional $200M milestone payment from Sarepta.
Claim 30% Off TipRanks
Forget margin or options. Here's how the pros trade SRPTPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead issues statement on exclusive license agreement with Sarepta
- Hold Rating on Arrowhead Pharmaceuticals Amid Uncertainty in Partnership with Sarepta Therapeutics
- Arrowhead falls -11.5%
- Arrowhead falls -8.9%
- Cautious Hold Rating on Arrowhead Pharmaceuticals Amid Uncertainty in Sarepta Partnership